B
ABBV icon

Bailard’s AbbVie ABBV Stock Holding History

Bailard’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$11.6M Sell
53,382
-2,864
-5% -$635K 0.27% 85
2025
Q4 		$12.9M Buy
56,246
+10,893
+24% +$2.48M 0.28% 73
2025
Q3 		$10.5M Buy
45,353
+16,049
+55% +$3.27M 0.23% 95
2025
Q2 		$5.44M Buy
29,304
+11,693
+66% +$2.17M 0.13% 129
2025
Q1 		$3.69M Buy
17,611
+148
+0.8% +$28.8K 0.1% 163
2024
Q4 		$3.1M Sell
17,463
-45
-0.3% -$8.27K 0.08% 180
2024
Q3 		$3.46M Buy
17,508
+20
+0.1% +$3.73K 0.09% 179
2024
Q2 		$3M Sell
17,488
-3,277
-16% -$543K 0.08% 191
2024
Q1 		$3.78M Sell
20,765
-166
-0.8% -$28.6K 0.1% 166
2023
Q4 		$3.24M Sell
20,931
-182
-0.9% -$26.5K 0.1% 176
2023
Q3 		$3.15M Sell
21,113
-88
-0.4% -$12.9K 0.1% 164
2023
Q2 		$2.86M Sell
21,201
-6,752
-24% -$990K 0.1% 161
2023
Q1 		$4.45M Buy
27,953
+10
+0% +$1.53K 0.16% 119
2022
Q4 		$4.52M Sell
27,943
-52
-0.2% -$7.97K 0.17% 114
2022
Q3 		$3.76M Sell
27,995
-65
-0.2% -$9.33K 0.16% 126
2022
Q2 		$4.3M Sell
28,060
-200
-0.7% -$30.6K 0.17% 115
2022
Q1 		$4.58M Sell
28,260
-786
-3% -$114K 0.15% 129
2021
Q4 		$3.93M Buy
29,046
+800
+3% +$94.5K 0.13% 145
2021
Q3 		$3.05M Buy
28,246
+45
+0.2% +$5.14K 0.1% 157
2021
Q2 		$3.18M Sell
28,201
-1,677
-6% -$189K 0.11% 157
2021
Q1 		$3.23M Buy
29,878
+23,715
+385% +$2.54M 0.12% 152
2020
Q4 		$660K Buy
6,163
+192
+3% +$18.5K 0.03% 270
2020
Q3 		$523K Sell
5,971
-2,424
-29% -$228K 0.03% 274
2020
Q2 		$824K Buy
8,395
+798
+11% +$70.3K 0.05% 214
2020
Q1 		$579K Buy
7,597
+1,427
+23% +$122K 0.04% 214
2019
Q4 		$546K Sell
6,170
-1,824
-23% -$151K 0.03% 261
2019
Q3 		$605K Sell
7,994
-345
-4% -$23.7K 0.04% 242
2019
Q2 		$606K Sell
8,339
-236
-3% -$18.6K 0.04% 262
2019
Q1 		$691K Sell
8,575
-616
-7% -$50.4K 0.04% 254
2018
Q4 		$847K Buy
9,191
+1,213
+15% +$107K 0.06% 232
2018
Q3 		$755K Buy
7,978
+863
+12% +$81.8K 0.04% 247
2018
Q2 		$659K Sell
7,115
-4,115
-37% -$402K 0.04% 282
2018
Q1 		$1.06M Sell
11,230
-75
-0.7% -$8.24K 0.07% 213
2017
Q4 		$1.09M Buy
11,305
+6,265
+124% +$590K 0.07% 227
2017
Q3 		$448K Hold
5,040
– – 0.03% 222
2017
Q2 		$365K Sell
5,040
-1,437
-22% -$96.6K 0.03% 225
2017
Q1 		$422K Buy
6,477
+1,031
+19% +$64.8K 0.04% 221
2016
Q4 		$341K Sell
5,446
-547
-9% -$33.4K 0.03% 236
2016
Q3 		$378K Buy
5,993
+564
+10% +$36.5K 0.03% 222
2016
Q2 		$336K Buy
+5,429
New +$331K 0.04% 231
2014
Q4 		– Sell
-3,642
Closed -$210K – 233
2014
Q3 		$210K Buy
+3,642
New +$202K 0.03% 222

Other funds holding ABBV

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Bailard's ABBV Position: Q1 2026 in Review

Bailard reduced its AbbVie (ABBV) stake by 5.1% in Q1 2026, selling an estimated $635K and leaving 53,382 shares worth $11.6M. The position accounts for 0.27% of the portfolio, ranked #85.

Bailard first reported a position in ABBV in Q3 2014 and has held it in 41 quarters since. The position peaked at $12.9M in Q4 2025. 4,076 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • Bailard held 53,382 shares of AbbVie worth $11.6M as of Q1 2026.
  • Bailard sold 2,864 AbbVie shares in Q1 2026, an estimated $635K.
  • AbbVie made up 0.27% of Bailard's portfolio in Q1 2026, its #85 holding.
  • Bailard first reported a position in AbbVie in Q3 2014 and has held it in 41 quarters since.
  • Bailard's AbbVie position peaked at $12.9M in Q4 2025.
  • 4,076 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Bailard's 13F filing for Q1 2026, filed 11 May 2026.